Oral Mucositis Treatment Market Report 2026

The oral mucositis treatment market size has grown strongly in recent years. It will grow from $2.14 billion in 2025 to $2.36 billion in 2026 at a compound annual growth rate (CAGR) of 10%. The growth in the historic period can be attributed to increased use of chemotherapy and radiotherapy, high incidence of treatment-induced mucositis, expansion of oncology supportive care, availability of oral rinses, rising hospital oncology services.

The oral mucositis treatment market size is expected to see strong growth in the next few years. It will grow to $3.44 billion in 2030 at a compound annual growth rate (CAGR) of 9.9%. The growth in the forecast period can be attributed to growth in cancer treatment volumes, increasing adoption of laser therapy, rising focus on supportive oncology care, advancements in mucosal healing agents, expansion of outpatient cancer care. Major trends in the forecast period include increasing use of laser therapy for oral mucositis, growing adoption of preventive oral care protocols, rising demand for topical and supportive therapies, expansion of home-based oral mucositis care, increasing focus on improving cancer patient quality of life.

The growing use of chemotherapy is expected to drive the expansion of the oral mucositis treatment market in the coming years. Chemotherapy is a medical therapy that employs powerful chemicals to kill or inhibit the growth of cancer cells. Its increased use is fueled by its effectiveness in targeting cancer cells, offering patients a higher chance of remission and improved survival rates. Oral mucositis treatments help alleviate pain, promote healing, and prevent complications associated with chemotherapy, thereby enhancing patient comfort during treatment. For example, in February 2025, University College London, a UK-based multidisciplinary public research university, reported that fewer lung cancer patients in the UK (27.7%) received chemotherapy compared to Canada (35%), Norway (45.3%), and Australia (41.4%). Consequently, the rising use of chemotherapy is fueling growth in the oral mucositis treatment market.

Leading companies in the oral mucositis treatment market are focusing on developing advanced quick pain relief products to enhance patient comfort, improve treatment adherence, and support better recovery outcomes. Quick pain relief products are designed to rapidly reduce pain and maintain relief over time without causing a sharp, burning, or irritating sensation upon application. For example, in October 2024, Jaguar Health, a U.S.-based company, launched Gelclair, an FDA-approved prescription product for managing and relieving oral mucositis pain. This innovative treatment features a protective gel action and soothing application, helping alleviate pain and support oral function in cancer patients. Gelclair is highly effective, providing rapid pain relief and mucosal protection, making it an ideal therapy for oral mucositis by enhancing comfort and supporting oral function during cancer treatment.

In March 2023, EVERSANA, a U.S.-based full-service commercialization partner for life sciences companies, partnered with ChemoMouthpiece LLC to support the U.S. launch and commercialization of the Chemo Mouthpiece, an intra-oral cooling medical device designed to help cancer patients manage and treat oral mucositis. Through this collaboration, EVERSANA aims to utilize its expertise in market access, regulatory support, analytics, pricing, and distribution to accelerate patient access, streamline the commercial rollout, and maximize adoption of the device within the oncology supportive care segment. ChemoMouthpiece LLC is a U.S.-based medical device company specializing in intra-oral cryotherapy solutions for chemotherapy-induced oral mucositis.

Major companies operating in the oral mucositis treatment market are Sanofi S.A., Alliance Pharma plc, Galera Therapeutics Inc., Soligenix Inc., Innovation Pharmaceuticals Inc., EUSA Pharma, Norgine B.V., Aspen Pharmacare Holdings Limited, Enzychem Lifesciences Corporation, EpicentRx Inc., Monopar Therapeutics Inc., Oragenics Inc., Soleva Pharma LLC, Colgate-Palmolive Company, Sunstar Group, Camurus AB, Swedish Orphan Biovitrum AB (Sobi), Jaguar Health Inc., CANbridge Pharmaceuticals Inc., Amgen Inc.

North America was the largest region in the oral mucositis treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oral mucositis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the oral mucositis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the oral mucositis treatment market by increasing the cost of imported laser devices, pharmaceutical drugs, and oral care consumables used in supportive oncology care. These effects are most evident in oncology centers across North America, Europe, and Asia Pacific, where treatment protocols rely on specialized equipment and therapies. Rising tariff related expenses have contributed to higher overall treatment costs and budget pressure for cancer care providers. This has influenced procurement decisions and adoption of advanced supportive care solutions. However, tariffs have encouraged local manufacturing of supportive care products, expanded domestic oral therapy production, and strengthened regional supply chains over the long term.

The oral mucositis treatment market research report is one of a series of new reports that provides oral mucositis treatment market statistics, including oral mucositis treatment industry global market size, regional shares, competitors with a oral mucositis treatment market share, detailed oral mucositis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the oral mucositis treatment industry. This oral mucositis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Oral mucositis treatment refers to therapies designed to prevent or manage inflammation and ulceration of the mouth’s mucous membranes, commonly caused by chemotherapy or radiation. These treatments help reduce discomfort, prevent infections, promote oral healing, and improve the quality of life for cancer patients undergoing intensive therapies.

The main types of oral mucositis treatment include pharmaceutical drugs, laser therapy, cryotherapy, oral rinses and mouthwashes, and other approaches. Pharmaceutical drugs are used to diagnose, treat, or prevent disease by influencing the body’s functions or processes. They can be administered orally, intravenously, subcutaneously, topically, or via other routes. These treatments are indicated for specific causes, including chemotherapy-induced and radiotherapy-induced oral mucositis, among others. Distribution channels include online pharmacies, retail pharmacies, hospital pharmacies, and direct sales. End-users include hospitals, homecare settings, ambulatory surgical centers, and long-term care facilities.

The oral mucositis treatment market consists of revenues earned by entities by providing services such as pain management, and antimicrobial treatments. The market value includes the value of related goods sold by the service provider or included within the service offering. The oral mucositis treatment market also includes sales of topical anesthetics, and anti-inflammatory agents. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.